Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E David G McIntosh

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Expert Review of Vaccines|July 24, 2004
Cost-effectiveness studies of pneumococcal conjugate vaccinesE David G McIntosh
Advances in Experimental Medicine and Biology|March 14, 2009
Paediatric drug development and clinical trialsE David G McIntosh
Handbook of Experimental Pharmacology|October 24, 2012
Efflux: how bacteria use pumps to control their microenvironmentE David G McIntosh
Expert Review of Anti-Infective Therapy|October 7, 2005
Treatment and prevention strategies to combat pediatric pneumococcal meningitisE David G McIntosh
Therapeutic Advances in Vaccines and Immunotherapy|July 13, 2018
Healthcare-associated infections: potential for prevention through vaccinationE David G McIntosh
Expert Review of Vaccines|December 18, 2010
Global prevailing and emerging pediatric pneumococcal serotypesE David G McIntosh, Ralf R Reinert
Vaccine|January 18, 2003
Recent progress in the development of vaccines for infants and childrenE David G McIntosh, Peter R Paradiso
Expert Review of Vaccines|November 17, 2011
Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policiesMarco A P Sáfadi, E David G McIntosh
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 17, 2013
Potential cost-effectiveness of pneumococcal conjugate vaccine (PCV) in TurkeyOzden Türel, Adnan Kisa, E David G McIntosh, et al.
Vaccine|May 15, 2003
The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccineE David G McIntosh, Peter Conway, Julie Willingham, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Expert Review of Vaccines|July 24, 2004
Cost-effectiveness studies of pneumococcal conjugate vaccinesE David G McIntosh
Advances in Experimental Medicine and Biology|March 14, 2009
Paediatric drug development and clinical trialsE David G McIntosh
Handbook of Experimental Pharmacology|October 24, 2012
Efflux: how bacteria use pumps to control their microenvironmentE David G McIntosh
Expert Review of Anti-Infective Therapy|October 7, 2005
Treatment and prevention strategies to combat pediatric pneumococcal meningitisE David G McIntosh
Therapeutic Advances in Vaccines and Immunotherapy|July 13, 2018
Healthcare-associated infections: potential for prevention through vaccinationE David G McIntosh
Expert Review of Vaccines|December 18, 2010
Global prevailing and emerging pediatric pneumococcal serotypesE David G McIntosh, Ralf R Reinert
Vaccine|January 18, 2003
Recent progress in the development of vaccines for infants and childrenE David G McIntosh, Peter R Paradiso
Expert Review of Vaccines|November 17, 2011
Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policiesMarco A P Sáfadi, E David G McIntosh
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 17, 2013
Potential cost-effectiveness of pneumococcal conjugate vaccine (PCV) in TurkeyOzden Türel, Adnan Kisa, E David G McIntosh, et al.
Vaccine|May 15, 2003
The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccineE David G McIntosh, Peter Conway, Julie Willingham, et al.
Pageof 2